Cancer therapy breakthrough: Vaccine cuts skin cancer recurrence risk in landmark trial
A groundbreaking vaccine for melanoma, or skin cancer, has shown promising results in a Phase 3 trial conducted by Moderna and Merck. The vaccine, known as intismeran autogene, is personalized, tailored specifically to each patient's unique tumor. The treatment identifies and targets specific mutations present in the cancer cells, but not in normal cells, by using mRNA instructions.
The vaccine is combined with Keytruda, a well-known cancer immunotherapy, to enhance the immune system's ability to recognize and destroy residual cancer cells. The study involved 1,137 patients with high-risk stage IIB to IV melanoma, and the results demonstrated a reduction in both the risk of melanoma recurrence and the spread of the disease to distant parts of the body.
While the treatment is not a cure, it represents a significant step forward in the evolution of cancer treatment, providing additional clinical benefit when added to existing immunotherapy. However, the personalized nature of the vaccine poses challenges in terms of manufacturing, scalability, and cost, which may affect its widespread availability.
Written by urgent.news from The Indian Express's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
